When genomic scientist Daniel MacArthur had the opportunity to set up a new Centre for Population Genomics in Australia in 2019, he jumped at the chance to return home after 12 years living overseas.
Based in Boston as co-director of the Medical and Population Genomics Program at the Broad Institute for Mendelian Genomics at MIT and Harvard, his work in the US had involved using new genomic technologies to help predict and diagnose diseases.
It included overseeing a team that built one of the largest genetic data bases ever assembled, collecting data from more than 140,000 people.
MacArthur saw the new centre – a joint initiative of the Garvan Institute in Sydney and the Murdoch Children’s Institute in Melbourne – as the chance to bring his years of expertise in genomic medicine back to Australia.
“The centre’s focus is applying a lot of the lessons we had learned in the early days in building the field of genomic medicine, particularly in places like the US and the UK, and applying it in the context of the Australian community,” MacArthur says.
MacArthur will outline his vision for genomic medicine in Australia at the Sohn Hearts & Mind Conference in Sydney on Friday.
The conference, which features top fund managers from Australia and around the world giving their best stock tips, has raised $60m for medical research in Australia since it began in 2016.
This is the first year that The Centre for Population Genomics, which has been funded from a combination of government grants and philanthropy, will receive funding from the conference.
MacArthur says his aim at the conference will be to explain the potential of the developing field of genomic medicine in Australia, adding that it is “an exciting time for the field”.
While genetics involves the study of how a person’s genes can cause a disease or an illness, the newer field of genomics involves the study of all of a person’s genes – the genome – looking at how the combination of genetic factors and environment can cause disease.
“All conditions, including the big killers like heart disease and cancer, have a contribution from both our DNA and the environment,” MacArthur says.
“If we can better understand the DNA component, it makes it a lot easier for us to identify the people who are most at risk of those conditions and give them the information they might need to make lifestyle changes, and also to think about how we might be able to develop therapies which could reduce the risk of those conditions.”
MacArthur’s work has included understanding the basis of certain rare genetic disorders, which can cause diseases such as muscular dystrophy and which particularly affect children.
Working in Boston, he oversaw a program that sequenced and analysed genomic data from more than 10,000 people from families with rare diseases – work that contributed to the discovery of more than 100 new rare disease genes.
‘We can now think about making precise changes to someone’s DNA’
Daniel MacArthur, genomic scientist
But Australia’s racial mix – which includes many people from Asia, the Middle East and South Pacific – is very different to that in the European nations that have provided the basis for a lot of genomic medicine research to date.
“My driving purpose with the centre is thinking about ways we can make sure the benefit of new technologies is available to all Australians, regardless of their background,” MacArthur said.
“We are focused on working directly with communities to build up a better picture of the patterns of genetic variation that exist within the Australian community and use it to predict and build better tools for the diagnosis, prediction and treatment of disease.”
When MacArthur left Australia, in 2007, after completing his PhD in human genetics at the University of Sydney, there was little work being done in the field of genomics. “But since then, there has been a huge amount of work to build up the infrastructure and the approaches to it,” he says.
“The centre, is a partnership between two different institutions in Sydney and Melbourne, is a new approach to bringing together genetic information at a very large scale in a way which can benefit Australian communities, not just the ones that are already being studied in other places around the world.”
MacArthur is based in Sydney and oversees a team that has members in Sydney, Melbourne and New Zealand.
One of his goals is to build a genomic data base from about 10,000 people from specific groups in Australia, including people from the Pacific, Southeast Asia, the Middle East and East Africa, to help study diseases in those populations.
“More than a quarter of Australian citizens were born overseas and more than half have at least one parent born overseas,” he says. “It is essential we have a genetic resource which is fit for purpose in our own country, which captures the full spectrum of diversity which exists here.”
He says the study of genomic medicine is now taking off as a result of a combination of factors including a sharp drop in the cost of the technology involved.
“The first human genome, which took about 10 years to sequence by a team of scientists around the world, was released in 2003, and took about $3bn to generate,” he says. “These days we can sequence a genome for less than $1000. It takes a week and is more accurate than the genome we generated back in 2003.
“It is an almost unprecedented drop in the cost of the technology which allows us to think about applying genomics to so many people around the world and so many patients.”
Big advances in data science such as cloud computing and the broader availability of artificial intelligence have also allowed for much easier processing of huge amounts of data.
“These technologies are now the key factor in our ability to make sense of the data and use it to diagnose, predict and treat disease,” MacArthur says.
There have also been big advances in the drugs and therapeutics available to treat diseases.
“It means we can now think about making precise changes to someone’s DNA in ways which can help cure their condition, or even potentially prevent a condition that they might go on to develop in future,” MacArthur says.
The Australian is a media partner of Sohn Hearts & Minds which will be held at the Sydney Opera House this Friday, November 17.
This article was originally posted by The Australian here.
Licensed by Copyright Agency. You must not copy this work without permission.
Grounds, Fowler, and Weiss set up the Australian version, the Sohn Hearts & Minds conference in 2016, with the first meeting at the Sydney Opera House.
Healthcare stocks – from sleep apnoea giant ResMed, to cancer diagnostic biotech Telix Pharmaceuticals – were recommended at the Sohn Hearts & Minds Investment Leaders Conference on Friday.
Munro Partners partner Kieran Moore believes London-listed money transfer company Wise could see its share price soar 50 per cent by 2025, as its problem-solving business model gains traction while benefiting from higher interest rates.
Institutional investors such as super and pension funds are investing in private equity at “exactly the wrong time”, a top hedge fund manager has warned, as sharply higher interest rates threaten a wave of bankruptcies.
The world’s highest-profile tech investor, Cathie Wood, might be bruised but she is certainly bullish. Nor is she holding back. “I have always hated searching on Google,” she says of the search giant.
Cathie Wood has rightly called several of the big themes driving markets this year. But the world’s most divisive investor says we’re thinking about AI in the wrong way.
Tech investment guru Cathie Wood is still a big believer in bitcoin, so it was fitting that she chose Grayscale Bitcoin Trust as her stock pick for the 2023 Sohn Hearts & Minds Investment Leaders Conference.
Speaking at the Sohn Hearts & Minds conference on Friday, the Future Fund’s chief investment officer Ben Samild said it had traded around $65 billion worth of its portfolio for assets with better protection against what is expected to be a long-term inflationary environment.
When Damian Lewis, the actor who plays the ruthless hedge fund boss in the drama series Billions was looking for inspiration, he sat down with Daniel Loeb.
The US financial sector is not without its problems but Ravi Chopra backs Webster Financial Corporation as his stock pick for the 2023 Sohn Hearts & Minds Investment Leaders Conference.
It might be time to look beyond big name, overpriced Wall Street stocks that could struggle to deliver growth. That was the message from top fund managers, company founders and super funds at the Sohn Hearts & Minds Conference.
A year on from the start of ChatGPT, the Future Fund hasn’t decided how to play this phase of the AI revolution but is open to the possibility it will be a major boost to productivity.
The Future Fund, Australia’s $200 billion sovereign wealth fund, has been sounding the alarm on the developed world’s rising levels of debt, the prospect of higher inflation, and the risks in the bond market for longer than most.
Most hedge fund managers brag about their wins and shy away from their losses – Martin Hughes is not most hedge fund managers.
Bryce and Ren from Equity Mates are joined by Ashish Swarup is a Portfolio Manager and Investment Analyst at Aikya Investment Management
Australia’s best stock pickers have just eight minutes to convince the country’s top money managers they have found an investment gem that the market has overlooked.
Daniel Loeb of Third Point says the way companies are dealing with the high cost of debt is delivering new opportunities.
When genomic scientist Daniel MacArthur had the opportunity to set up a new Centre for Population Genomics in Australia in 2019, he jumped at the chance to return home after 12 years living overseas.
European leisure and luxury – a designer handbag, a last-minute flight to Monte Carlo, a stay in a five-star hotel – is where many choose to spend their hard-earned cash. For Sharif el Khazen, it’s where he makes it.
Mining stocks are poised to rise amid tight supply for key commodities such as copper, nickel and uranium, says Terra Capital founder Jeremy Bond.
The culture at Ray Dalio’s massive hedge fund has been a source of intrigue, and with a new book, controversy. Atul Lele says it’s made him a better investor.
Global growth fund manager Munro Partners will have a difficult task choosing a single company to tip to an audience of industry heavyweights at the Sohn Hearts & Minds conference.
Sheila Patel says it’s time for the venture capital sector to “grow up” and higher rates will help do that. VC firms need to think differently about how they invest.
Melbourne scientist Misty Jenkins has had a long-time interest in immunology. But it was a neuroscientist friend who urged her to focus her skills on seeking a cure for brain cancer.
Tom Naughton is Managing Partner and CIO at Prusik Investment and speak with Equity Mates ahead of his appearance at the Hearts and Minds conference.
A true contrarian investor, Chris Kourtis can find himself sounding a lot like a bull when in the company of bears, and there’s a lot to be bearish about at the moment.
As soon as the three musketeers [Guy Fowler, Matthew Grounds and Gary Weiss] spoke to me I said ‘stop’. They said ‘we haven’t finished’. And I said, ‘I’m in’. We invested $10 million in Sohn Hearts and Minds. So substantial enough for a young fellow like me.
Famed hedge fund manager Dan Loeb has been named as one of the headline acts for next month’s Sohn Hearts & Minds philanthropic investment conference to be held in Sydney. Mr Loeb, 61, has built a reputation as a fierce shareholder activist and oversees $US11.7 billion ($18.5 billion) at New York-based Third Point.
When Ravi Chopra reveals his stock pick at the prestigious Sohn Hearts & Minds conference at the Opera House in Sydney next month, it could well be a short bet on a US bank.
Bryce and Ren from Equity Mates are joined by Rikki Bannan, Executive Director and Portfolio Manager at IFM Investors.
Last year, Ravi Chopra was travelling through Europe to shop his latest short idea to potential investors. "Financials are really all in the weeds," Ravi Chopra shared with The Australian Financial Review. "It’s all about numbers, it’s about modeling. It’s not just about looking at earnings reports, but also diving into regulatory data.
“Healthcare is often viewed as a stable, defensive sector to invest in, but in small caps that hasn’t necessarily proven to be the case,” she says in an interview with The Australian ahead of her appearance as a stock tipper at the Sohn Hearts & Minds conference in Sydney next month.
According to Dr Attia - who will speak at the Sohn Hearts & Minds in Sydney next month - nothing is completely random. He has built a career unearthing about what fuels a long life and shared his knowledge in the bestselling book Outlive: The Science & Art of Longevity.
Angela Aldrich bet against Treasury Wine Estates at the top of the market; now the Bayberry Capital founder is preparing to make her next big call.
After a decade of easy money pushing equity markets in one direction, Wall Street hedge fund manager Ricky Sandler says the return of volatility and higher interest rates is seeing money return to long-short strategies.
When New York-based hedge fund manager Ricky Sandler arrived in Australia a year ago to spend time with his son who was studying in Sydney, he didn’t expect to become the reigning champion of a philanthropic investor conference.